Achillion Pharmaceuticals (ACHN) 12.27 $ACHN
Jim Cramer's 'Mad Money' Recap: The 2012 Stock Market All Over Again
at The Street - Tue Sep 02, 6:49PM CDT
Investors are dumping the industrial and technology stocks in favor of anything domestic, including health care, transportation, restaurants and entertainment, Cramer says.
Reveal Insider Trading for Facebook, Plug Power, Achillion Pharmaceuticals, Apple, Twitter, and Intel
PR Newswire - Tue Sep 02, 7:55AM CDT
Today, Insiderslab.com revealed the latest insider trading research for Facebook (NASDAQ: FB), Plug Power (NASDAQ: PLUG), Achillion Pharmaceuticals (NASDAQ: ACHN), Apple (NASDAQ: AAPL), Twitter (NYSE: TWTR), and Intel (NASDAQ:INTC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Most active Nasdaq-traded stocks
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology and Intercept Pharmaceuticals
PR Newswire - Wed Aug 27, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Roche (OTC:RHHBY-Free Report), InterMune (Nasdaq:ITMN-Free Report), Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report), Puma Biotechnology (NYSE
BYI-Free Report) and Intercept Pharmaceuticals (Nasdaq:ICPT-Free Report).
Achillion Pharmaceuticals (ACHN) Jumps: Stock Adds 9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:37AM CDT
Achillion Pharmaceuticals, Inc. (ACHN) was a big mover last session, as the company saw its shares rise 9% on the day.
Nasdaq stocks posting largest percentage increases
AP - Tue Aug 26, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Achillion Pharmaceuticals (ACHN) Stock Hits New One-Year High
at The Street - Tue Aug 26, 11:10AM CDT
Achillion Pharmaceuticals (ACHN) touched another 52-week high of $12 on Tuesday after UBS tabbed the company as a possible takeover target.
3 Biotechs Surging Following InterMune Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:07AM CDT
InterMune 's (ITMN) impending acquisition by Roche (RHHBY) caused many mid-cap biotechs to rise.
Critical Alerts For Achillion Pharmaceuticals, Intel, YY, JA Solar and Skullcandy Released By InvestorsObserver
PR Newswire - Tue Aug 26, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACHN, INTC, YY, JASO and SKUL.
'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.
Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 5:25PM CDT
The EMA accepted Cubist Pharmaceuticals' (CBST) MAA for its investigational antibiotic, ceftolozane/tazobactam.
More Biotech Mergers: Roche to Acquire InterMune (ITMN) - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Aug 25, 3:43PM CDT
Roche is looking to buy InterMune, sending shares of ITMN up over 35 percent on the day.
Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
at The Street - Mon Aug 25, 1:27PM CDT
Achillion Pharmaceuticals (ACHN) surged to a 52-week high of $11.15 in afternoon trading Monday after UBS tabbed the company as a possible takeover target.
Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:00PM CDT
Achillion's (ACHN) shares touched a 52-week high of $10.18 on Aug 20 following its announcement that the USPTO has granted a patent to the company.
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Jim Cramer's 'Mad Money' Recap: The 2012 Stock Market All Over Again
at The Street - Tue Sep 02, 6:49PM CDT
Investors are dumping the industrial and technology stocks in favor of anything domestic, including health care, transportation, restaurants and entertainment, Cramer says.
Reveal Insider Trading for Facebook, Plug Power, Achillion Pharmaceuticals, Apple, Twitter, and Intel
PR Newswire - Tue Sep 02, 7:55AM CDT
Today, Insiderslab.com revealed the latest insider trading research for Facebook (NASDAQ: FB), Plug Power (NASDAQ: PLUG), Achillion Pharmaceuticals (NASDAQ: ACHN), Apple (NASDAQ: AAPL), Twitter (NYSE: TWTR), and Intel (NASDAQ:INTC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Most active Nasdaq-traded stocks
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology and Intercept Pharmaceuticals
PR Newswire - Wed Aug 27, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Roche (OTC:RHHBY-Free Report), InterMune (Nasdaq:ITMN-Free Report), Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report), Puma Biotechnology (NYSE
BYI-Free Report) and Intercept Pharmaceuticals (Nasdaq:ICPT-Free Report). Achillion Pharmaceuticals (ACHN) Jumps: Stock Adds 9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:37AM CDT
Achillion Pharmaceuticals, Inc. (ACHN) was a big mover last session, as the company saw its shares rise 9% on the day.
Nasdaq stocks posting largest percentage increases
AP - Tue Aug 26, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Achillion Pharmaceuticals (ACHN) Stock Hits New One-Year High
at The Street - Tue Aug 26, 11:10AM CDT
Achillion Pharmaceuticals (ACHN) touched another 52-week high of $12 on Tuesday after UBS tabbed the company as a possible takeover target.
3 Biotechs Surging Following InterMune Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:07AM CDT
InterMune 's (ITMN) impending acquisition by Roche (RHHBY) caused many mid-cap biotechs to rise.
Critical Alerts For Achillion Pharmaceuticals, Intel, YY, JA Solar and Skullcandy Released By InvestorsObserver
PR Newswire - Tue Aug 26, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACHN, INTC, YY, JASO and SKUL.
'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.
Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 5:25PM CDT
The EMA accepted Cubist Pharmaceuticals' (CBST) MAA for its investigational antibiotic, ceftolozane/tazobactam.
More Biotech Mergers: Roche to Acquire InterMune (ITMN) - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Aug 25, 3:43PM CDT
Roche is looking to buy InterMune, sending shares of ITMN up over 35 percent on the day.
Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
at The Street - Mon Aug 25, 1:27PM CDT
Achillion Pharmaceuticals (ACHN) surged to a 52-week high of $11.15 in afternoon trading Monday after UBS tabbed the company as a possible takeover target.
Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:00PM CDT
Achillion's (ACHN) shares touched a 52-week high of $10.18 on Aug 20 following its announcement that the USPTO has granted a patent to the company.
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
